White Pine Capital LLC Invests $261,000 in NeoGenomics, Inc. (NASDAQ:NEO)

White Pine Capital LLC bought a new position in NeoGenomics, Inc. (NASDAQ:NEO) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 16,105 shares of the medical research company’s stock, valued at approximately $261,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BluePath Capital Management LLC purchased a new stake in NeoGenomics during the 3rd quarter valued at about $30,000. WINTON GROUP Ltd purchased a new stake in NeoGenomics during the 3rd quarter valued at about $133,000. Corton Capital Inc. purchased a new stake in NeoGenomics during the 3rd quarter valued at about $141,000. Aigen Investment Management LP purchased a new stake in NeoGenomics during the 3rd quarter valued at about $163,000. Finally, Mackenzie Financial Corp purchased a new stake in NeoGenomics during the 3rd quarter valued at about $199,000. 98.50% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total transaction of $38,701.52. Following the sale, the general counsel now owns 34,866 shares in the company, valued at approximately $521,595.36. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

NEO has been the topic of several recent analyst reports. William Blair reissued an “outperform” rating on shares of NeoGenomics in a research report on Wednesday, February 21st. Piper Sandler upped their target price on shares of NeoGenomics from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. The Goldman Sachs Group upped their target price on shares of NeoGenomics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, Needham & Company LLC upped their target price on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.50.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO traded up $0.29 during trading on Friday, hitting $14.14. The company’s stock had a trading volume of 830,782 shares, compared to its average volume of 638,425. The company has a 50-day moving average of $15.04 and a 200-day moving average of $15.92. NeoGenomics, Inc. has a 12 month low of $11.03 and a 12 month high of $21.22. The company has a debt-to-equity ratio of 0.57, a current ratio of 6.20 and a quick ratio of 5.95. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of -20.20 and a beta of 1.10.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings data on Tuesday, February 20th. The medical research company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.05. NeoGenomics had a negative net margin of 14.87% and a negative return on equity of 4.13%. The firm had revenue of $155.55 million for the quarter, compared to analysts’ expectations of $152.90 million. On average, sell-side analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.